Next Article in Journal
High Genetic Diversity despite Conserved Karyotype Organization in the Giant Trahiras from Genus Hoplias (Characiformes, Erythrinidae)
Next Article in Special Issue
The Unique Biology behind the Early Onset of Breast Cancer
Previous Article in Journal
Remodeling of Neurotransmission, Chemokine, and PI3K-AKT Signaling Genomic Fabrics in Neuropsychiatric Systemic Lupus Erythematosus
Previous Article in Special Issue
Characterization of New ATM Deletion Associated with Hereditary Breast Cancer
Open AccessReview

Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients

1
G.RE.T.A. Group for Reconstructive and Therapeutic Advancements, 80100 Naples, Italy
2
Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10001, USA
3
Breast Center, University Hospital of Basel, 4056 Basel, Switzerland
4
Department of Oncology and Haematology (DIPO), University of Milan, 20122 Milan, Italy
5
Division of Early Drug Development for Innovative Therapy, European Institute of Oncology, IRCCS, 20122 Milan, Italy
6
G.RE.T.A. Group for Reconstructive and Therapeutic Advancements, 20122 Milan, Italy
7
Multidisciplinary Breast Unit, Azienda Ospedaliera Cannizzaro, 95021 Catania, Italy
8
Surrey and Sussex Health Care, NHS Trust, London W1W 5EF, UK
9
Institute of Polymers, Composites and Biomaterials—National Research Council of Italy, 80125 Naples, Italy
10
G.RE.T.A. Group for Reconstructive and Therapeutic Advancements, 95021 Catania, Italy
*
Author to whom correspondence should be addressed.
Genes 2021, 12(2), 253; https://doi.org/10.3390/genes12020253
Received: 4 January 2021 / Revised: 23 January 2021 / Accepted: 27 January 2021 / Published: 10 February 2021
(This article belongs to the Special Issue Breast Cancer Genetics: Diagnostic and Treatment)
Growing numbers of asymptomatic women who become aware of carrying a breast cancer gene mutation (BRCA) mutation are choosing to undergo risk-reducing bilateral mastectomies with immediate breast reconstruction. We reviewed the literature with the aim of assessing the oncological safety of nipple-sparing mastectomy (NSM) as a risk-reduction procedure in BRCA-mutated patients. Nine studies reporting on the incidence of primary breast cancer post NSM in asymptomatic BRCA mutated patients undergoing risk-reducing bilateral procedures met the inclusion criteria. NSM appears to be a safe option for BRCA mutation carriers from an oncological point of view, with low reported rates of new breast cancers, low rates of postoperative complications, and high levels of satisfaction and postoperative quality of life. However, larger multi-institutional studies with longer follow-up are needed to establish this procedure as the best surgical option in this setting. View Full-Text
Keywords: breast cancer; BRCA mutations; risk reduction; nipple-sparing mastectomies breast cancer; BRCA mutations; risk reduction; nipple-sparing mastectomies
Show Figures

Figure 1

MDPI and ACS Style

Rocco, N.; Montagna, G.; Criscitiello, C.; Nava, M.B.; Privitera, F.; Taher, W.; Gloria, A.; Catanuto, G. Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. Genes 2021, 12, 253. https://doi.org/10.3390/genes12020253

AMA Style

Rocco N, Montagna G, Criscitiello C, Nava MB, Privitera F, Taher W, Gloria A, Catanuto G. Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients. Genes. 2021; 12(2):253. https://doi.org/10.3390/genes12020253

Chicago/Turabian Style

Rocco, Nicola; Montagna, Giacomo; Criscitiello, Carmen; Nava, Maurizio B.; Privitera, Francesca; Taher, Wafa; Gloria, Antonio; Catanuto, Giuseppe. 2021. "Nipple Sparing Mastectomy as a Risk-Reducing Procedure for BRCA-Mutated Patients" Genes 12, no. 2: 253. https://doi.org/10.3390/genes12020253

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop